Why Eli Lilly stock is down 3% today: FDA adverse event data explained
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
RBC Capital on Eli Lilly (LLY): 'we think the sell-off is overdone'
May 4, 2026 10:26 AM EDTRBC Capital analyst Trung Huynh reiterated an Outperform rating and $1,250.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Bottom line: We think one hepatic case in ~3,500 commercial patients is well within the range LLY demonstrated in clinical trials. Hepatic events occur... More
Goldman Sachs on Eli Lilly (LLY): 'see the stock weakness as an overreaction'
May 4, 2026 9:27 AM EDTGoldman Sachs analyst Asad Haider reiterated a Buy rating and $1,283.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Shares of LLY are down ~2% in early trading following a post in the FDA Adverse event monitoring system of a patient... More
Eli Lilly (LLY) PT Raised to $1,400 at Barclays, 'A remarkably strong quarter...and LLY's only just getting started'
May 4, 2026 8:58 AM EDTBarclays analyst Emily Field raised the price target on Eli Lilly (NYSE: LLY) to $1,400.00 (from $1,350.00) while maintaining a Overweight rating.
The analyst comments "A remarkably strong quarter...and LLY's only just getting started. Reiterate OW rating and raise PT to $1,400: We update our model following LLY's 1Q26 report (see Eli Lilly & Co: 1Q26 First Take: Mounjaro ex-US (+ a bit of US price) drive DD% top and bottom line beat & raise...call to focus on Foundayo (04/30/26)...where... More
Wolfe Research Defending Eli Lilly (LLY) Amid 1.53% Drop: 'Faers For Foundayo Are Unfounded'
May 4, 2026 8:57 AM EDTWolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $1,325.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "FAERS reports hepatic safety signal for Foundayo. On April 30th, the FDA received data via its FDA Adverse Event Reporting System (FAERS) suggesting that a patient dosed with Lilly (LLY)'s Foundayo, an oral small-molecule GLP-1, reported a case of serious hepatic failure. Given the importance of Foundayo's safety profile in unlocking the broader PCP prescribing opportunity, we reached out to LLY for further color behind the signal. Here, the company largely... More
